Abstract
Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Reviews on Recent Clinical Trials
Title: Pharmacokinetic Properties of Rituximab
Volume: 3 Issue: 1
Author(s): Jose Rodriguez and Antonio Gutierrez
Affiliation:
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Abstract: Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Export Options
About this article
Cite this article as:
Rodriguez Jose and Gutierrez Antonio, Pharmacokinetic Properties of Rituximab, Reviews on Recent Clinical Trials 2008; 3 (1) . https://dx.doi.org/10.2174/157488708783330495
DOI https://dx.doi.org/10.2174/157488708783330495 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids
Current Genomics Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Withdrawal Notice: Prognosis And Prediction Of Breast Cancer (Bc) Using Growing Mlt (Machine Learning Techniques)
Recent Advances in Computer Science and Communications Synthesis and Antitumor Activity Evaluation of 2-Aminothiazoles Appended 5-methylisoxazoline and Pyridine-piperazine Hybrid Molecules
Letters in Organic Chemistry The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Parenteral Drug Delivery: A Review
Recent Patents on Drug Delivery & Formulation Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy HIV Infection Induces Morphometrical Changes on the Oral (Buccal Mucosa and Tongue) Epithelial Cells
Current HIV Research The Evolution of Medical Imaging in the Therapeutics of Patients with Skin Cancer
Current Medical Imaging